Protalix BioTherapeutics (PLX) Tops Q1 EPS by 3c, Revenues Beat

May 14, 2021 6:51 AM EDT
Get Alerts PLX Hot Sheet
Price: $2.05 --0%

Revenue Growth %: -47.7%

Financial Fact:

Today's EPS Names:
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of ($0.14), $0.03 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $11.32 million versus the consensus estimate of $10.95 million.

"While the receipt of the Complete Response Letter last month from the FDA was disappointing, we are encouraged that the FDA did not report any potential safety or efficacy concerns for PRX-102," said Dror Bashan, Protalix's President and Chief Executive Officer. "We are working closely with the FDA and anticipate the required inspection and subsequent assessment will be completed once the FDA's travel restrictions are lifted. We continue to advance our earlier stage pipeline and anticipate continued progress throughout 2021. We are grateful for the support of our clinicians, patients, shareholders, Board members, employees and external partners and look forward to building stockholder value," concluded Mr. Bashan.

For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Earnings, Management Comments

Related Entities

Earnings, FDA